{"id":1343,"date":"2016-08-11T12:17:14","date_gmt":"2016-08-11T10:17:14","guid":{"rendered":"https:\/\/dev.medizone.com\/?p=1343"},"modified":"2017-09-06T11:27:33","modified_gmt":"2017-09-06T09:27:33","slug":"coherus-biosciences-announces-positive-phase-iii-results-for-chs-1420-humira-biosimilar-candidate-in-psoriasis-patients","status":"publish","type":"post","link":"https:\/\/medizone.com\/en\/coherus-biosciences-announces-positive-phase-iii-results-for-chs-1420-humira-biosimilar-candidate-in-psoriasis-patients\/","title":{"rendered":"Coherus BioSciences announces positive Phase III results for CHS-1420 (Humira biosimilar candidate) in psoriasis patients"},"content":{"rendered":"<p>Coherus BioSciences, Inc., reported topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab (Humira) biosimilar candidate.<\/p>\n<p>The study met its primary endpoint demonstrating similarity between CHS-1420 and Humira with respect to percentage of subjects achieving 75% improvement in psoriasis area and severity index (PASI-75) at Week 12. The 95% confidence intervals for the difference between treatment groups fell well within the prespecified margin. Both CHS-1420 and Humira were similarly well tolerated with similar safety profiles in this study.<\/p>\n<p>This was a confirmatory, randomized, double-blind, active-control, parallel-group, 3-part study in patients with active, moderate to severe, chronic plaque psoriasis. In treatment period 2, half the subjects randomized to Humira will cross-over to CHS-1420, modeling a chronic patient\u2019s transition to a biosimilar. Comparative safety, including immunogenicity, and durability of response to CHS-1420 and Humira at week 16 and 24 are key secondary endpoints. These data will be presented at an upcoming scientific conference. The full dataset through treatment period 2 will be available in Q4 2016 and included in the BLA submission to follow.<\/p>\n<p>Source: Biosimilar News<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Coherus BioSciences, Inc., reported topline results from an ongoing Phase 3 clinical study of CHS-1420, an adalimumab (Humira) biosimilar candidate. The study met its primary endpoint demonstrating similarity between CHS-1420 and Humira with respect to percentage of subjects achieving 75% improvement in psoriasis area and severity index (PASI-75) at Week 12. The 95% confidence intervals [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[16],"tags":[],"class_list":["post-1343","post","type-post","status-publish","format-standard","hentry","category-biosimilar-development"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/posts\/1343","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/comments?post=1343"}],"version-history":[{"count":2,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/posts\/1343\/revisions"}],"predecessor-version":[{"id":1345,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/posts\/1343\/revisions\/1345"}],"wp:attachment":[{"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/media?parent=1343"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/categories?post=1343"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizone.com\/en\/wp-json\/wp\/v2\/tags?post=1343"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}